LCP
ALPN

Lamond Capital Partners’s Alpine Immune Sciences Inc ALPN Stock Holding History

Lamond Capital Partners’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-56,250
Closed -$3.41M – 12
2015
Q2 		$3.41M Buy
+56,250
New +$3.35M 3.46% 10

Other funds holding ALPN

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Lamond Capital Partners's ALPN Position: Q3 2015 in Review

Lamond Capital Partners sold out of Alpine Immune Sciences Inc (ALPN) in Q3 2015, closing a stake of 56,250 shares — an estimated $3.41M sold.

Lamond Capital Partners first reported a position in ALPN in Q2 2015 and held it in 1 quarter. The position peaked at $3.41M in Q2 2015. 63 funds tracked by Wall St. Rank hold ALPN as of Q3 2015.

  • Lamond Capital Partners reported no remaining Alpine Immune Sciences Inc position as of Q3 2015 after selling out during the quarter.
  • Lamond Capital Partners sold 56,250 Alpine Immune Sciences Inc shares in Q3 2015, an estimated $3.41M.
  • Lamond Capital Partners first reported a position in Alpine Immune Sciences Inc in Q2 2015 and held it in 1 quarter.
  • Lamond Capital Partners's Alpine Immune Sciences Inc position peaked at $3.41M in Q2 2015.
  • 63 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q3 2015.

Based on Lamond Capital Partners's 13F filing for Q3 2015, filed 9 Nov 2015.